Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)

被引：0

作者：

Moehler, M. ^{[1
]}

Wyrwicz, L. ^{[2
]}

Chen, C. ^{[3
]}

Davenport, E. ^{[4
]}

Wang, J. ^{[4
]}

Nathani, R. ^{[3
]}

Kondo, K. ^{[3
]}

Elimova, E. ^{[5
]}

机构：

[1] Johannes Gutenberg Univ Mainz, Mainz, Germany

[2] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] RTI Int, Res Triangle Pk, NC USA

[5] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O-10

引用

页码：S185 / S185

页数：1

共 50 条

[21] Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
Sugarman, Ryan
Nunna, Sasikiran
Betts, Keith A.
Nie, Xiaoyu
Nguyen, Hiep
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[22] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
Sullivan, Kendall
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
[23] First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Liu, Tianshu
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Ruihua
Guo, Weijian
Qin, Shukui
Yang, Nong
Lu, Jianwei
Shitara, Kohei
Lei, Ming
Li, Mingshun
Bao, Nicole
Chen, Tian
Shen, Lin
INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (04) : 749 - 760
[24] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
McCraith, Stephen
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
[25] Health-related quality of life (HRQoL) in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) treated with nivolumab (N) plus chemotherapy (CT) or nivo plus ipilimumab (I) versus chemo: Results from CheckMate 648
Bridgewater, John A.
Chau, Ian
Gricar, Joseph
Blum, Steven I.
Taylor, Fiona
Lawrance, Rachael
Padilla, Brad
Yip, Christine
Wyrwicz, Lucjan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[26] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649
Wyrwicz, L. S.
Shitara, K.
Moehler, M.
Ajani, J. A.
Shen, L.
Garrido, M.
Gallardo Araneda, C. E.
Yamaguchi, K.
Cleary, J.
Elimova, E.
Bruges Maya, R.
Karamouzis, M. V.
Skoczylas, T.
Bragagnoli, A. C.
Liu, T.
Tehfe, M.
Feeney, K.
Wang, R.
Zhang, J.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2024, 35 : S169 - S170
[27] Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses
Janjigian, Yelena Y.
Shitara, Kohei
Ajani, Jaffer
Moehler, Markus
Yao, Jin
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Schenker, Michael
Yanez, Patricio
Kowalyszyn, Ruben
Karamouzis, Michalis
Zander, Thomas
Feeney, Kynan
Elimova, Elena
Nathani, Raheel
Novosiadly, Ruslan
Lei, Ming
CANCER RESEARCH, 2023, 83 (08)
[28] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
Cruz-Correa, Marcia
Xu, Rui-Hua
Moehler, Markus H.
Oh, Do-Youn
Kato, Ken
Spigel, David R.
Arkenau, Hendrik-Tobias
Tabernero, Josep
Zimina, Anastasia V.
Bai, Yuxian
Shi, Jianhua
Lee, Keun-Wook
Hirano, Hidekazu
Wyrwicz, Lucjan S.
Pazo Cid, Roberto
Xu, Hui
Sheng, Tao
Barnes, Gisoo
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 290 - 290
[29] Q-TWiST analysis of nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) in patients with PD-L1 CPS≥1 and CPS≥5: 4-year follow-up from CheckMate 649 (CM 649)
Lin, D.
Quan, W.
Garretson, M.
Chirikov, V. V.
Chen, C.
Singh, P.
Davis, C.
Sugarman, R.
ANNALS OF ONCOLOGY, 2024, 35 : S170 - S170
[30] Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)
Lin, Daniel
Quan, Wenying
Garretson, Marne
Chirikov, Viktor
Chen, Clara
Singh, Prianka
Davis, Catherine
Sugarman, Ryan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →